Benchmark against your competition
Understand how AI crawlers access your site
See where AI gets info about you
Track the queries mentioning your brand
Own your AI narrative
Add GEO to your service offerings
Get recommended in shopping queries
Monitor AI mentions at scale
Viking Therapeutics, Inc.
What AI says about Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on creating innovative therapies for metabolic and endocrine disorders. Their pipeline includes several compounds currently in clinical trials aimed at treating conditions such as obesity, non-alcoholic steatohepatitis (NASH), and rare diseases.
Is this your brand?
Claim this profile to keep your information accurate and add what's missing.
Not in this profile yet:
Products & Services
VK2735
A dual agonist for the treatment of various metabolic disorders.
VK2809
An orally available small molecule for treating lipid and metabolic disorders.
VK0214
A small molecule for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).
VK5211
Therapeutic for hip fracture and muscle wasting.
VK0612
Therapeutic for Type 2 Diabetes.
VK1430
Therapeutic for hypertriglyceridemia and NASH.
Common Questions
What types of disorders does Viking Therapeutics focus on?
Viking Therapeutics focuses on metabolic and endocrine disorders.
What is VK2735?
VK2735 is a novel dual agonist for the treatment of various metabolic disorders.
Is there any ongoing clinical research?
Yes, Viking has several compounds currently in clinical trials.
What is the purpose of VK2809?
VK2809 is developed for the treatment of lipid and metabolic disorders.
What is VK0214 used for?
VK0214 is being developed for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).